Windlas Biotech Reports Record Revenue of Rs. 760 Cr. in FY25 with 20% YoY Growth

Windlas Biotech Limited, a leading player in the domestic pharmaceutical formulations CDMO industry in India, reported its audited financials for the quarter and year ended March 31, 2025. The company recorded a revenue of Rs. 759.9 crores in FY25, a growth of 20.4% YoY. EBITDA stood at Rs. 94.1 crores, a growth of 20.4% YoY. PAT stood at Rs. 61.0 crores, a growth of 4.8% YoY. The CDMO vertical contributed approximately 73% to the consolidated revenue. The Trade Generics & Institutional vertical contributed approximately 23% to the consolidated revenue. The Exports vertical contributed approximately 4% to the consolidated revenue. The company achieved its highest-ever earnings per share (EPS) in FY25 (Rs 29.19) post listing.